Werner Verbiest

753 total citations
12 papers, 576 citations indexed

About

Werner Verbiest is a scholar working on Virology, Infectious Diseases and Emergency Medicine. According to data from OpenAlex, Werner Verbiest has authored 12 papers receiving a total of 576 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Virology, 11 papers in Infectious Diseases and 2 papers in Emergency Medicine. Recurrent topics in Werner Verbiest's work include HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (11 papers) and HIV/AIDS Research and Interventions (9 papers). Werner Verbiest is often cited by papers focused on HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (11 papers) and HIV/AIDS Research and Interventions (9 papers). Werner Verbiest collaborates with scholars based in Canada, Belgium and United States. Werner Verbiest's co-authors include Brendan Larder, Kurt Hertogs, Veronica Miller, P. Richard Harrigan, Robin Wood, Scott A. Wegner, Joan Montaner, Alex R. Rinehart, Neil M.H. Graham and Susan C. Hunt and has published in prestigious journals such as AIDS, JAIDS Journal of Acquired Immune Deficiency Syndromes and Antiviral Therapy.

In The Last Decade

Werner Verbiest

12 papers receiving 551 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Werner Verbiest Canada 8 540 511 59 34 27 12 576
Judith Workman United Kingdom 9 375 0.7× 331 0.6× 75 1.3× 35 1.0× 31 1.1× 10 422
Ian McGowan United States 6 464 0.9× 362 0.7× 108 1.8× 25 0.7× 41 1.5× 11 492
Maria Pia De Pasquale Italy 9 284 0.5× 231 0.5× 66 1.1× 17 0.5× 21 0.8× 12 343
Greet Beets United States 6 364 0.7× 298 0.6× 123 2.1× 60 1.8× 40 1.5× 8 430
Isabelle Farfara France 7 292 0.5× 331 0.6× 105 1.8× 18 0.5× 27 1.0× 11 374
Carol Fridlund United States 10 336 0.6× 292 0.6× 129 2.2× 18 0.5× 20 0.7× 11 391
Shujia Liang China 15 524 1.0× 472 0.9× 211 3.6× 32 0.9× 35 1.3× 68 634
Christiane Adjé-Touré United States 13 404 0.7× 413 0.8× 87 1.5× 10 0.3× 15 0.6× 19 560
Samir Vora Switzerland 6 324 0.6× 296 0.6× 79 1.3× 20 0.6× 8 0.3× 11 363
Bill Guyer United States 8 417 0.8× 320 0.6× 71 1.2× 20 0.6× 33 1.2× 11 445

Countries citing papers authored by Werner Verbiest

Since Specialization
Citations

This map shows the geographic impact of Werner Verbiest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Werner Verbiest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Werner Verbiest more than expected).

Fields of papers citing papers by Werner Verbiest

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Werner Verbiest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Werner Verbiest. The network helps show where Werner Verbiest may publish in the future.

Co-authorship network of co-authors of Werner Verbiest

This figure shows the co-authorship network connecting the top 25 collaborators of Werner Verbiest. A scholar is included among the top collaborators of Werner Verbiest based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Werner Verbiest. Werner Verbiest is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Breckenridge, A, JH Darbyshire, Ade Fakoya, et al.. (2005). A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance. UCL Discovery (University College London). 2 indexed citations
2.
Hertogs, Kurt, et al.. (2003). Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.. PubMed. 8(5). 395–402. 5 indexed citations
3.
Harrigan, P. Richard, Kurt Hertogs, Werner Verbiest, et al.. (2003). Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy. Antiviral Therapy. 8(5). 395–402. 5 indexed citations
4.
Baxter, John D., Thomas C. Merigan, Deborah Wentworth, et al.. (2002). Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS. 16(8). 1131–1138. 37 indexed citations
5.
Cohen, Calvin, Susan C. Hunt, Michael Sension, et al.. (2002). A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 16(4). 579–588. 126 indexed citations
6.
Cheingsong, Rachanee, Thierry H. Roels, Chantal Maurice, et al.. (2001). High Prevalence of Genotypic and Phenotypic HIV-1 Drug-Resistant Strains Among Patients Receiving Antiretroviral Therapy in Abidjan, Côte d'Ivoire. JAIDS Journal of Acquired Immune Deficiency Syndromes. 26(5). 501–506. 82 indexed citations
7.
Harrigan, P. Richard, Joan Montaner, Scott A. Wegner, et al.. (2001). World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS. 15(13). 1671–1677. 95 indexed citations
8.
Cheingsong, Rachanee, Thierry H. Roels, Chantal Maurice, et al.. (2001). High Prevalence of Genotypic and Phenotypic HIV-1 Drug-Resistant Strains Among Patients Receiving Antiretroviral Therapy in Abidjan, Côte d'Ivoire. JAIDS Journal of Acquired Immune Deficiency Syndromes. 26(5). 501–506. 33 indexed citations
9.
Verbiest, Werner, Stephen Brown, Calvin Cohen, et al.. (2001). Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study. AIDS. 15(5). 647–650. 16 indexed citations
10.
Harrigan, P. Richard, Kurt Hertogs, Werner Verbiest, et al.. (1999). Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS. 13(14). 1863–1871. 101 indexed citations
11.
Miller, Veronica, Thomas Stark, J. De Crée, et al.. (1996). Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS. 10(5). F1–F7. 72 indexed citations
12.
Verhaegen, H., et al.. (1995). A simple and rapid flow cytometric method to measure lymphocyte activation in HIV+ subjects. Diminished response to pokeweed mitogen in early disease.. PubMed. 8(4). 345–55. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Judith Workman Breakdown of academic impact, for papers by Ian McGowan Breakdown of academic impact, for papers by Maria Pia De Pasquale Breakdown of academic impact, for papers by Greet Beets Breakdown of academic impact, for papers by Isabelle Farfara Breakdown of academic impact, for papers by Carol Fridlund Breakdown of academic impact, for papers by Shujia Liang Breakdown of academic impact, for papers by Christiane Adjé-Touré Breakdown of academic impact, for papers by Samir Vora Breakdown of academic impact, for papers by Bill Guyer
Rankless by CCL
2026